Neuroinflammatory mechanisms may help identify candidate biomarkers in chronic traumatic encephalopathy (CTE).
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic reasoning without empirical data or systematic synthesis
PubMed 40666430 · doi:10.17879/freeneuropathology-2025-6382
What was done
This narrative review synthesized literature on neuroinflammation in chronic traumatic encephalopathy (CTE) resulting from repetitive head impacts. The authors evaluated the biological mechanisms and theoretical utility of specific inflammatory and damage-related immune mediators—specifically CCL11 (Eotaxin-1), CCL21, and glial fibrillary acidic protein (GFAP)—as candidate diagnostic biomarkers.
What was found
The abstract reports no numerical findings, effect estimates, sample sizes, or quantitative diagnostic accuracy metrics (such as sensitivity or specificity values). It presents a conceptual argument that specific neuroinflammatory signatures may distinguish CTE pathology and serve as diagnostic markers or therapeutic targets.
Why it matters
CTE currently lacks validated in vivo diagnostic tools and can only be definitively diagnosed post-mortem. Identifying specific neuroinflammatory biomarkers could enable earlier clinical detection in living at-risk populations, such as contact sport athletes and military personnel.
Limits
This is a narrative review presenting theoretical arguments rather than new human data or a systematic review. The abstract provides no quantitative data, no diagnostic performance statistics, and no direct clinical validation in living cohorts.
Cited by
- supports Chronic traumatic encephalopathy (CTE) can continue to progress and worsen even after repetitive head trauma has ceased due to an ongoing feed-forward neuroinflammatory process.